{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:58:34Z","timestamp":1790697514428,"version":"4.1.0"},"reference-count":81,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,30]],"date-time":"2021-08-30T00:00:00Z","timestamp":1630281600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81571319"],"award-info":[{"award-number":["81571319"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81801679"],"award-info":[{"award-number":["81801679"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81871052"],"award-info":[{"award-number":["81871052"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006606","name":"Natural Science Foundation of Tianjin City","doi-asserted-by":"publisher","award":["17JCZDJC35700"],"award-info":[{"award-number":["17JCZDJC35700"]}],"id":[{"id":"10.13039\/501100006606","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.jad.2021.08.023","type":"journal-article","created":{"date-parts":[[2021,8,23]],"date-time":"2021-08-23T11:05:38Z","timestamp":1629716738000},"page":"163-172","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Clozapine induces metformin-resistant prediabetes\/diabetes that is associated with poor clinical efficacy in patients with early treatment-resistant schizophrenia"],"prefix":"10.1016","volume":"295","author":[{"given":"Chuanjun","family":"Zhuo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haibo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunhua","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaocui","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailin","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongjun","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianchen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayue","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuli","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiliang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anqu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoyong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongguang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jad.2021.08.023_bib0001","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1177\/0706743717719899","article-title":"Canadian guidelines for the assessment and diagnosis of patients with schizophrenia spectrum and other psychotic disorders","volume":"62","author":"Addington","year":"2017","journal-title":"Can. J. Psychiatry"},{"key":"10.1016\/j.jad.2021.08.023_bib0003","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jpsychires.2020.07.034","article-title":"Progression of neuroanatomical abnormalities after first-episode of psychosis: a 3-year longitudinal sMRI study","volume":"130","author":"Akudjedu","year":"2020","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.jad.2021.08.023_bib0004","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.psychres.2015.10.036","article-title":"Does cognitive impairment in treatment-resistant and ultra-treatment-resistant schizophrenia differ from that in treatment responders?","volume":"230","author":"Anderson","year":"2015","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.jad.2021.08.023_bib0005","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1176\/appi.ajp.2017.17040409","article-title":"Diabetes and schizophrenia-new findings for an old puzzle","volume":"174","author":"Andreassen","year":"2017","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2021.08.023_bib0006","article-title":"Medical treatments are also part of God\u2019s gift\": holy water attendants\u2019 perspectives on a collaboration between spiritual and psychiatric treatment for mental illness in Ethiopia","volume":"25","author":"Asher","year":"2021","journal-title":"Transcult. Psychiatry"},{"key":"10.1016\/j.jad.2021.08.023_bib0007","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1097\/WNF.0000000000000404","article-title":"One plus one sometimes equals more than two: long-acting injectable aripiprazole adjunction in clozapine-resistant schizophrenia","volume":"43","author":"Balcioglu","year":"2020","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.jad.2021.08.023_bib0009","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/YIC.0b013e32801182e6","article-title":"Insulin counter-regulatory factors, fibrinogen and C-reactive protein during olanzapine administration: effects of the antidiabetic metformin","volume":"22","author":"Baptista","year":"2007","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2021.08.023_bib0011","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/0269881119889296","article-title":"Evidence-based guidelines for the pharmacological treatment of schizophrenia: updated recommendations from the British Association for Psychopharmacology","volume":"34","author":"Barnes","year":"2020","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.jad.2021.08.023_bib0012","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1192\/j.eurpsy.2020.72","article-title":"Clozapine and paliperidone palmitate antipsychotic combination in treatment-resistant schizophrenia and other psychotic disorders: a retrospective 6-month mirror-image study","volume":"63","author":"Bioque","year":"2020","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.jad.2021.08.023_bib0013","doi-asserted-by":"crossref","first-page":"70","DOI":"10.9740\/mhc.2020.05.070","article-title":"Clozapine and hematologic adverse reactions: impact of the Risk Evaluation and Mitigation Strategy program","volume":"10","author":"Borrelli","year":"2020","journal-title":"Ment. Health Clin."},{"key":"10.1016\/j.jad.2021.08.023_bib0015","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/YIC.0000000000000336","article-title":"The effects of adding long-acting injectable antipsychotic drugs to clozapine on relapse and hospitalization in patients with treatment-resistant schizophrenia: a mirror-image retrospective study","volume":"36","author":"Caliskan","year":"2021","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2021.08.023_bib0016","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.schres.2020.12.002","article-title":"Characteristics and definitions of ultra-treatment-resistant schizophrenia - a systematic review and meta-analysis","volume":"228","author":"Campana","year":"2021","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.jad.2021.08.023_bib0017","article-title":"Predictors of treatment-resistant and clozapine-resistant schizophrenia: a 12-year follow-up study of first-episode schizophrenia-spectrum disorders","author":"Chan","year":"2020","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.jad.2021.08.023_bib0019","article-title":"Could N-acetylcysteine improve the safety of clozapine?","author":"Chr\u00e9tien","year":"2020","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.jad.2021.08.023_bib0020","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD006324.pub2","article-title":"Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia","volume":"8","author":"Cipriani","year":"2009","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.jad.2021.08.023_bib0021","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1111\/dom.14246","article-title":"No effects of dapagliflozin, metformin or exercise on plasma glucagon concentrations in individuals with prediabetes: a post hoc analysis from the randomized controlled PRE-D trial","volume":"23","author":"Clemmensen","year":"2021","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.jad.2021.08.023_bib0022","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1007\/s40265-020-01393-x","article-title":"Pharmacological management of glucose dysregulation in patients treated with second-generation antipsychotics","volume":"80","author":"Cernea","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.jad.2021.08.023_bib0024","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1177\/0269881116645254","article-title":"BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment","volume":"30","author":"Cooper","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.jad.2021.08.023_bib0025","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1097\/JGP.0b013e3181e56cdc","article-title":"Prediabetes assessment and follow-up in older veterans with schizophrenia","volume":"18","author":"Copeland","year":"2010","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"10.1016\/j.jad.2021.08.023_bib0026","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/wps.20714","article-title":"Metformin add-on vs. antipsychotic switch vs. continued antipsychotic treatment plus healthy lifestyle education in overweight or obese youth with severe mental illness: results from the IMPACT trial","volume":"19","author":"Correll","year":"2020","journal-title":"World Psychiatry"},{"key":"10.1016\/j.jad.2021.08.023_bib0027","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12888-020-02992-4","article-title":"Study protocol of a randomized, double-blind, placebo-controlled, multi-center trial to treat antipsychotic-induced weight gain: the Metformin-Lifestyle in antipsychotic users (MELIA) trial","volume":"21","author":"de Boer","year":"2021","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.jad.2021.08.023_bib0029","doi-asserted-by":"crossref","first-page":"e01351","DOI":"10.1002\/brb3.1351","article-title":"Individuals in the prediabetes stage exhibit reduced hippocampal tail volume and executive dysfunction","volume":"9","author":"Dong","year":"2019","journal-title":"Brain Behav."},{"key":"10.1016\/j.jad.2021.08.023_bib0031","doi-asserted-by":"crossref","first-page":"652","DOI":"10.5694\/j.1326-5377.2005.tb06860.x","article-title":"Weight gain and diabetes with \u201csecond-generation\u201d antipsychotic drugs","volume":"182","author":"Firestone","year":"2005","journal-title":"Med. J. Aust."},{"key":"10.1016\/j.jad.2021.08.023_bib0032","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1093\/bmb\/ldaa024","article-title":"Clozapine in the treatment of refractory schizophrenia: a practical guide for healthcare professionals","volume":"135","author":"Flanagan","year":"2020","journal-title":"Br. Med. Bull."},{"key":"10.1016\/j.jad.2021.08.023_bib0033","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1093\/schbul\/sbw027","article-title":"Awareness of Pre-diabetes or Diabetes and Associated Factors in People With Psychosis","volume":"42","author":"Foley","year":"2016","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.jad.2021.08.023_bib0035","doi-asserted-by":"crossref","DOI":"10.3390\/cells8111336","article-title":"Second-generation antipsychotics and dysregulation of glucose metabolism: beyond weight gain","volume":"8","author":"Grajales","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.jad.2021.08.023_bib0036","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/wps.20518","article-title":"Long-term antipsychotic treatment of schizophrenia: does it help or hurt over a 20-year period?","volume":"17","author":"Harrow","year":"2018","journal-title":"World Psychiatry"},{"key":"10.1016\/j.jad.2021.08.023_bib0037","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S2215-0366(15)00310-7","article-title":"Genetic vulnerability in antipsychotic drug-induced diabetes","volume":"2","author":"Hasnain","year":"2015","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.jad.2021.08.023_bib0038","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/S2215-0366(16)30306-6","article-title":"Schizophrenia and metabolic dysregulation: shared roots?","volume":"3","author":"Hasnain","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.jad.2021.08.023_bib0040","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1177\/0269881105058379","article-title":"Diabetes and schizophrenia 2005: are we any closer to understanding the link?","volume":"19","author":"Holt","year":"2005","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.jad.2021.08.023_bib0041","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jpsychires.2020.09.026","article-title":"Diabetes in late-life schizophrenia: prevalence, factors, and association with clinical symptoms","volume":"132","author":"Huo","year":"2021","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.jad.2021.08.023_bib0042","article-title":"Treatment resistance in psychiatry: state of the art and new directions","volume":"13","author":"Howes","year":"2021","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.jad.2021.08.023_bib0043","doi-asserted-by":"crossref","first-page":"125","DOI":"10.2174\/157488631002150515120209","article-title":"Prevalence of cardiovascular and metabolic events in patients prescribed clozapine: a retrospective observational, clinical cohort study","volume":"10","author":"Hyde","year":"2015","journal-title":"Curr. Drug Saf."},{"key":"10.1016\/j.jad.2021.08.023_bib0044","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41398-020-0785-y","article-title":"Adjunctive metformin for antipsychotic-induced dyslipidemia: a meta-analysis of randomized, double-blind, placebo-controlled trials","volume":"10","author":"Jiang","year":"2020","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.jad.2021.08.023_bib0045","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1176\/appi.ajp.2020.177901","article-title":"The American psychiatric association practice guideline for the treatment of patients with schizophrenia","volume":"177","author":"Keepers","year":"2020","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2021.08.023_bib0046","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2019.109839","article-title":"Neuroanatomical profiles of treatment-resistance in patients with schizophrenia spectrum disorders","volume":"99","author":"Kim","year":"2020","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.jad.2021.08.023_bib0047","doi-asserted-by":"crossref","first-page":"174","DOI":"10.7570\/jomes20021","article-title":"Cognitive impairments and associated structural brain changes in metabolic syndrome and implications of neurocognitive intervention","volume":"29","author":"Kordestani-Moghadam","year":"2020","journal-title":"J. Obes. Metab. Syndr."},{"key":"10.1016\/j.jad.2021.08.023_bib0048","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1017\/S0033291718002957","article-title":"Neuropsychological function at first episode in treatment-resistant psychosis: findings from the \u00c6SOP-10 study","volume":"49","author":"Kravariti","year":"2019","journal-title":"Psychol. Med."},{"key":"10.1016\/j.jad.2021.08.023_bib0049","doi-asserted-by":"crossref","first-page":"3231","DOI":"10.1017\/S0033291716002014","article-title":"Two distinct patterns of treatment resistance: clinical predictors of treatment resistance in first-episode schizophrenia spectrum psychoses","volume":"46","author":"Lally","year":"2016","journal-title":"Psychol. Med."},{"key":"10.1016\/j.jad.2021.08.023_bib0050","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.schres.2018.02.035","article-title":"Cardio-metabolic risk and its management in a cohort of clozapine-treated outpatients","volume":"199","author":"Lappin","year":"2018","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.jad.2021.08.023_bib0051","first-page":"1","article-title":"High prevalence of prediabetes and metabolic abnormalities in overweight or obese schizophrenia patients treated with clozapine or olanzapine","author":"Larsen","year":"2018","journal-title":"CNS Spectr."},{"key":"10.1016\/j.jad.2021.08.023_bib0052","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1001\/jamapsychiatry.2017.1220","article-title":"Effect of liraglutide treatment on prediabetes and overweight or obesity in clozapine- or olanzapine-treated patients with schizophrenia spectrum disorder: a randomized clinical trial","volume":"74","author":"Larsen","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jad.2021.08.023_bib0053","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jad.2021.08.023_bib0054","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1038\/s41598-017-02884-w","article-title":"Time-dependent changes and potential mechanisms of glucose-lipid metabolic disorders associated with chronic clozapine or olanzapine treatment in rats","volume":"7","author":"Liu","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jad.2021.08.023_bib0055","article-title":"Metformin for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus","volume":"12","author":"Madsen","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.jad.2021.08.023_bib0056","doi-asserted-by":"crossref","first-page":"460","DOI":"10.4088\/JCP.10m06822","article-title":"Prediabetes in patients treated with antipsychotic drugs","volume":"73","author":"Manu","year":"2012","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2021.08.023_bib0058","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1001\/jamapsychiatry.2019.1702","article-title":"Association with hospitalization and all-cause discontinuation among patients with schizophrenia on clozapine vs other oral second-generation antipsychotics: a systematic review and meta-analysis of cohort studies","volume":"76","author":"Masuda","year":"2019","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jad.2021.08.023_bib0059","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.schres.2018.02.056","article-title":"Early treatment resistance in a Latin-American cohort of patients with schizophrenia","volume":"199","author":"Mena","year":"2018","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.jad.2021.08.023_bib0060","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1600-0447.2008.01317.x","article-title":"The metabolic syndrome and schizophrenia","volume":"119","author":"Meyer","year":"2009","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.jad.2021.08.023_bib0061","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.schres.2020.07.011","article-title":"Glucose homeostasis in unaffected first-degree relatives of schizophrenia patients: a systematic review and meta-analysis","volume":"223","author":"Misiak","year":"2020","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.jad.2021.08.023_bib0062","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1093\/schbul\/sbr148","article-title":"Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders\u2013a systematic review and meta-analysis","volume":"39","author":"Mitchell","year":"2013","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.jad.2021.08.023_bib0063","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.4103\/0366-6999.233944","article-title":"Metformin for antipsychotic-related metabolic syndrome in children: fact or fiction?","volume":"131","author":"Naguy","year":"2018","journal-title":"Chin. Med. J. (Engl.)"},{"issue":"Suppl 1","key":"10.1016\/j.jad.2021.08.023_bib0065","first-page":"1","article-title":"Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review","volume":"19","author":"Newcomer","year":"2005","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jad.2021.08.023_bib0066","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.neubiorev.2020.01.017","article-title":"Demographic and clinical features as predictors of clozapine response in patients with schizophrenia spectrum disorders: a systematic review and meta-analysis","volume":"111","author":"Okhuijsen-Pfeifer","year":"2020","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.jad.2021.08.023_bib0067","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S2215-0366(16)30262-0","article-title":"The association between first-episode psychosis and abnormal glycaemic control: systematic review and meta-analysis","volume":"3","author":"Perry","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.jad.2021.08.023_bib0068","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1001\/jamapsychiatry.2016.3803","article-title":"Impaired glucose homeostasis in first-episode schizophrenia: a systematic review and meta-analysis","volume":"74","author":"Pillinger","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jad.2021.08.023_bib0070","article-title":"Clozapine-induced microseizures, orofacial dyskinesia, and speech dysfluency in an adolescent with treatment resistant early onset schizophrenia on concurrent lithium therapy","volume":"2017","author":"Rachamallu","year":"2017","journal-title":"Case Rep. Psychiatry"},{"key":"10.1016\/j.jad.2021.08.023_bib0071","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1176\/appi.ajp.2016.16040442","article-title":"Endogenous and antipsychotic-related risks for diabetes mellitus in young people with schizophrenia: a Danish population-based cohort study","volume":"174","author":"Rajkumar","year":"2017","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2021.08.023_bib0072","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1176\/ajp.156.4.544","article-title":"Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder","volume":"156","author":"Robinson","year":"1999","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2021.08.023_bib0073","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1001\/jamapsychiatry.2015.2955","article-title":"Efficacy, acceptability, and tolerability of antipsychotics in treatment-resistant schizophrenia: a network meta-analysis","volume":"73","author":"Samara","year":"2016","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jad.2021.08.023_bib0074","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jpsychires.2020.02.015","article-title":"Metabolic measures 12 months after a randomised controlled trial of treatment of clozapine associated obesity and diabetes with exenatide (CODEX)","volume":"124","author":"Siskind","year":"2020","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.jad.2021.08.023_bib0076","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1111\/dom.13167","article-title":"Treatment of clozapine-associated obesity and diabetes with exenatide in adults with schizophrenia: a randomized controlled trial (CODEX)","volume":"20","author":"Siskind","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.jad.2021.08.023_bib0078","doi-asserted-by":"crossref","first-page":"641","DOI":"10.2337\/dc08-0403","article-title":"Random capillary blood glucose cut points for diabetes and pre-diabetes derived from community-based opportunistic screening in India","volume":"32","author":"Somannavar","year":"2009","journal-title":"Diabetes Care."},{"key":"10.1016\/j.jad.2021.08.023_bib0079","doi-asserted-by":"crossref","first-page":"e107","DOI":"10.1192\/bjo.2020.89","article-title":"Prevalence of treatment resistance and clozapine use in early intervention services","volume":"6","author":"Stokes","year":"2020","journal-title":"BJPsych Open"},{"key":"10.1016\/j.jad.2021.08.023_bib0080","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/eip.12225","article-title":"Body composition, pre-diabetes and cardiovascular disease risk in early schizophrenia","volume":"11","author":"Strassnig","year":"2017","journal-title":"Early Interv. Psychiatry"},{"key":"10.1016\/j.jad.2021.08.023_bib0081","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/wps.20567","article-title":"Management of common adverse effects of antipsychotic medications","volume":"17","author":"Stroup","year":"2018","journal-title":"World Psychiatry"},{"key":"10.1016\/j.jad.2021.08.023_bib0082","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph17186700","article-title":"Risk factors of metabolic syndrome in community-dwelling people with schizophrenia","volume":"17","author":"Sun","year":"2020","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"10.1016\/j.jad.2021.08.023_bib0083","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/acps.12982","article-title":"One-year follow-up on liraglutide treatment for prediabetes and overweight\/obesity in clozapine- or olanzapine-treated patients","volume":"139","author":"Svensson","year":"2019","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.jad.2021.08.023_bib0085","article-title":"From population to neuron: exploring common mediators for metabolic problems and mental illnesses","author":"Takayanagi","year":"2020","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.jad.2021.08.023_bib0086","article-title":"Exenatide, metformin, or both for prediabetes in PCOS: A randomized, open-labeled, parallel-group controlled study","author":"Tao","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.jad.2021.08.023_bib0087","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.neubiorev.2017.04.005","article-title":"The influence of the glutamatergic system on cognition in schizophrenia: a systematic review","volume":"77","author":"Thomas","year":"2017","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.jad.2021.08.023_bib0088","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2337\/dc19-0762","article-title":"White matter connectivity abnormalities in prediabetes and type 2 diabetes: the maastricht study","volume":"43","author":"Vergoossen","year":"2020","journal-title":"Diabetes Care."},{"key":"10.1016\/j.jad.2021.08.023_bib0090","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1007\/s00592-020-01559-9","article-title":"Metformin use in prediabetes: is earlier intervention better?","volume":"57","author":"Warrilow","year":"2020","journal-title":"Acta Diabetol."},{"key":"10.1016\/j.jad.2021.08.023_bib0091","article-title":"Clozapine initiation for schizophrenia: a review of clinical effectiveness and guidelines","author":"Wells","year":"2020","journal-title":"Can. Agency Drugs Technol. Health"},{"key":"10.1016\/j.jad.2021.08.023_bib0092","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1089\/cap.2018.29157.bjc","article-title":"Multidisciplinary management of adolescent early-onset, treatment-resistant schizophrenia complicated by avoidant\/restrictive food intake disorder and catatonia in acute exacerbations","volume":"28","author":"Westfall","year":"2018","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"10.1016\/j.jad.2021.08.023_bib0093","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1001\/jama.2007.56-b","article-title":"Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial","volume":"299","author":"Wu","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.jad.2021.08.023_bib0094","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1007\/s00213-006-0384-5","article-title":"Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia","volume":"186","author":"Wu","year":"2006","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.jad.2021.08.023_bib0095","doi-asserted-by":"crossref","first-page":"198","DOI":"10.2174\/1871530319666190614121738","article-title":"The association between HbA1c levels, olfactory memory and cognition in normal, pre-diabetic and diabetic persons","volume":"20","author":"Yulug","year":"2020","journal-title":"Endocr. Metab. Immune Disord. Drug Targets"},{"key":"10.1016\/j.jad.2021.08.023_bib0096","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1002\/hup.1220","article-title":"The prevalence and clinical-demographic correlates of diabetes mellitus in chronic schizophrenic patients receiving clozapine","volume":"26","author":"Zhang","year":"2011","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.jad.2021.08.023_bib0097","doi-asserted-by":"crossref","DOI":"10.1016\/j.psyneuen.2020.105061","article-title":"Sex differences in metabolic disorder patterns of first-episode drug-naive patients with schizophrenia","volume":"124","author":"Zhou","year":"2021","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.jad.2021.08.023_bib0098","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/j.euroneuro.2016.07.010","article-title":"A systematic review and meta-analysis of randomised controlled trials of treatments for clozapine-induced obesity and metabolic syndrome","volume":"26","author":"Zimbron","year":"2016","journal-title":"Eur. Neuropsychopharmacol."}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032721008211?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032721008211?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:57:32Z","timestamp":1790693852000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032721008211"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":81,"alternative-id":["S0165032721008211"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2021.08.023","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clozapine induces metformin-resistant prediabetes\/diabetes that is associated with poor clinical efficacy in patients with early treatment-resistant schizophrenia","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2021.08.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}